Chardan Capital Reiterates “Buy” Rating for iBio (NYSE:IBIO)
iBio (NYSE:IBIO – Get Free Report)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a research note issued on Monday,Benzinga reports. They currently have a $5.00 price target on the stock. Chardan Capital’s price target would indicate a potential upside of 488.24% from the company’s current price. Separately, StockNews.com upgraded shares of iBio […]
iBio (NYSE:IBIO – Get Free Report)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a research note issued on Monday,Benzinga reports. They currently have a $5.00 price target on the stock. Chardan Capital’s price target would indicate a potential upside of 488.24% from the company’s current price. Separately, StockNews.com upgraded shares of iBio […]
